AG
EPZM

Advisor Group’s Epizyme, Inc EPZM Stock Holding History

Advisor Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$4K Sell
145
-126
-46% -$1.87K ﹤0.01% 4800
2019
Q3 		$2K Hold
271
– – ﹤0.01% 5032
2019
Q2 		$4K Buy
271
+126
+87% +$1.62K ﹤0.01% 4805
2019
Q1 		$2K Hold
145
– – ﹤0.01% 4994
2018
Q4 		$1K Hold
145
– – ﹤0.01% 5040
2018
Q3 		$2K Hold
145
– – ﹤0.01% 4894
2018
Q2 		$2K Buy
+145
New +$2.26K ﹤0.01% 4721
2016
Q4 		– Sell
-2,693
Closed -$26K – 4687
2016
Q3 		$26K Buy
+2,693
New +$24.6K ﹤0.01% 2993

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisor Group's EPZM Position: Q4 2019 in Review

Advisor Group reduced its Epizyme, Inc (EPZM) stake by 46% in Q4 2019, selling an estimated $1.87K and leaving 145 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4800.

Advisor Group first reported a position in EPZM in Q3 2016 and has held it in 8 quarters since. The position peaked at $26K in Q3 2016. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.

  • Advisor Group held 145 shares of Epizyme, Inc worth $4K as of Q4 2019.
  • Advisor Group sold 126 Epizyme, Inc shares in Q4 2019, an estimated $1.87K.
  • Epizyme, Inc made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4800 holding.
  • Advisor Group first reported a position in Epizyme, Inc in Q3 2016 and has held it in 8 quarters since.
  • Advisor Group's Epizyme, Inc position peaked at $26K in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.